These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 30158208)

  • 21. Corporate communication of the relative health risks of IQOS through a webchat service.
    Braznell S; Branston JR; Gilmore AB
    Tob Control; 2023 Aug; 32(e2):e205-e211. PubMed ID: 35241501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Marketing IQOS in a dark market.
    Mathers A; Schwartz R; O'Connor S; Fung M; Diemert L
    Tob Control; 2019 Mar; 28(2):237-238. PubMed ID: 29724866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IQOS point-of-sale marketing strategies in Israel: a pilot study.
    Bar-Zeev Y; Levine H; Rubinstein G; Khateb I; Berg CJ
    Isr J Health Policy Res; 2019 Jan; 8(1):11. PubMed ID: 30642383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vascular endothelial function is impaired by aerosol from a single IQOS HeatStick to the same extent as by cigarette smoke.
    Nabavizadeh P; Liu J; Havel CM; Ibrahim S; Derakhshandeh R; Jacob Iii P; Springer ML
    Tob Control; 2018 Nov; 27(Suppl 1):s13-s19. PubMed ID: 30206183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evolving IQOS packaging designs change perceptions of product appeal, uniqueness, quality and safety: a randomised experiment, 2018, USA.
    Lee JGL; Blanchflower TM; O'Brien KF; Averett PE; Cofie LE; Gregory KR
    Tob Control; 2019 Aug; 28(e1):e52-e55. PubMed ID: 31164489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Examining perceptions about IQOS heated tobacco product: consumer studies in Japan and Switzerland.
    Hair EC; Bennett M; Sheen E; Cantrell J; Briggs J; Fenn Z; Willett JG; Vallone D
    Tob Control; 2018 Nov; 27(Suppl 1):s70-s73. PubMed ID: 29764957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Informing iQOS Regulations in the United States: A Synthesis of What We Know.
    Berg CJ; Bar-Zeev Y; Levine H
    Sage Open; 2020; 10(1):. PubMed ID: 32719733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of FDA's IQOS marketing authorisation and its policy impacts.
    Lempert LK; Glantz S
    Tob Control; 2020 Jun; ():. PubMed ID: 32601147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. United States Food and Drug Administration's authorization of reduced exposure claims for IQOS
    Eckford R; Severini G; Sebrié EM; Muggli ME; Beem A; Rosen D; Crosbie E
    Rev Panam Salud Publica; 2022; 46():e155. PubMed ID: 36245905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence and patterns of tobacco and/or nicotine product use in Japan (2017) after the launch of a heated tobacco product (
    Afolalu EF; Langer P; Fischer K; Roulet S; Magnani P
    F1000Res; 2021; 10():504. PubMed ID: 35528952
    [No Abstract]   [Full Text] [Related]  

  • 31. IQOS Marketing in the US: The Need to Study the Impact of FDA Modified Exposure Authorization, Marketing Distribution Channels, and Potential Targeting of Consumers.
    Berg CJ; Abroms LC; Levine H; Romm KF; Khayat A; Wysota CN; Duan Z; Bar-Zeev Y
    Int J Environ Res Public Health; 2021 Oct; 18(19):. PubMed ID: 34639851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IQOS is not an acronym: a call to researchers and journals.
    Seidenberg A; Freeman B
    Tob Control; 2021 May; 30(3):356-358. PubMed ID: 32300026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IQOS - a heat-not-burn (HnB) tobacco product - chemical composition and possible impact on oxidative stress and inflammatory response. A systematic review.
    Kopa PN; Pawliczak R
    Toxicol Mech Methods; 2020 Feb; 30(2):81-87. PubMed ID: 31532297
    [No Abstract]   [Full Text] [Related]  

  • 34. Point-of-sale marketing of heated tobacco products in Israel: cause for concern.
    Halpern-Felsher B
    Isr J Health Policy Res; 2019 May; 8(1):47. PubMed ID: 31133053
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of IQOS health warnings and modified risk claims among young adult cigarette smokers and non-smokers.
    Mays D; Johnson AC; Glasser A; Mercincavage M; Strasser AA
    Tob Control; 2023 Jul; 32(4):505-508. PubMed ID: 34716283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Household Surveys in the General Population and Web-Based Surveys in IQOS Users Registered at the Philip Morris International IQOS User Database: Protocols on the Use of Tobacco- and Nicotine-Containing Products in Germany, Italy, and the United Kingdom (Greater London), 2018-2020.
    Sponsiello-Wang Z; Langer P; Prieto L; Dobrynina M; Skiada D; Camille N; Weitkunat R; Lüdicke F
    JMIR Res Protoc; 2019 May; 8(5):e12061. PubMed ID: 31094340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Switching to the Tobacco Heating System Versus Continued Cigarette Smoking on Chronic Generalized Periodontitis Treatment Outcome: Protocol for a Randomized Controlled Multicenter Study.
    Pouly S; Ng WT; Benzimra M; Soulan A; Blanc N; Zanetti F; Picavet P; Baker G; Haziza C
    JMIR Res Protoc; 2021 Jan; 10(1):e15350. PubMed ID: 33459599
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of IQOS risk perceptions on cigarette smoking behaviours: results from a prospective pilot study.
    DeAtley T; Stone MD; Strasser AA; Audrain-McGovern J
    Tob Control; 2024 Feb; 33(2):263-266. PubMed ID: 36002165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of IQOS introduction on Philip Morris International cigarette sales in Spain: a Logarithmic Mean Divisa Index decomposition approach.
    Golpe AA; Martín-Álvarez JM; Galiano A; Asensio E
    Gac Sanit; 2022; 36(4):293-300. PubMed ID: 35219532
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An Overview of iQOS
    Başaran R; Güven NM; Eke BC
    Turk J Pharm Sci; 2019 Sep; 16(3):371-374. PubMed ID: 32454738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.